MoHFW Approves New "BPaLM" (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin) Treatment Regimen for Multidrug-Resistant Tuberculosis (MDR-TB).

Goverment Scheme

The Ministry of Health and Family Welfare (MoHFW) has approved the new BPaLM regimen for treating multidrug-resistant tuberculosis (MDR-TB). The BPaLM treatment includes a combination of four drugs: Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin. This new regimen offers a shorter, more effective treatment option for MDR-TB, which has been a significant public health challenge. By implementing BPaLM, the government aims to improve treatment outcomes and reduce the burden of TB in the country. The introduction of this regimen is a significant step forward in India’s fight against drug-resistant TB and improving patient care.


      The BPaLM regimen shortens MDR-TB treatment duration, enhancing patient compliance and treatment success rates.

      This approval is expected to reduce the spread of MDR-TB and improve overall TB management in India.

     

 

     


About MoHFW,

Minister : J. P. Nadda
Headquarters: New Delhi
          ____________________________